Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers find treatments that preserve ovarian function in young women with cancer

04.06.2003


Two studies by researchers at The University of Texas M. D. Anderson Cancer Center have identified treatments that appear helpful in preserving ovarian function in pre-menopausal women with cancer.



The unrelated analyses, to be presented at different times during the annual meeting of the American Society of Clinical Oncology, are the first to focus on the desire of many younger patients with breast as well as other cancers to maintain fertility, as well as to protect their bones, hearts, and sexual functioning.

One study, led by Nuhad K. Ibrahim, M.D., associate professor of breast medical oncology, found that breast cancer patients who used a paclitaxel-based chemotherapy regimen may preserve ovarian function compared with patients treated just with standard chemotherapy.


The other analysis, conducted by Naoto Ueno, M.D., Ph.D., assistant professor of blood and marrow transplantation, concluded that patients treated with "mini" allogeneic transplants for a variety of cancers also had a significantly greater chance of protecting their ovaries compared to patients given high dose chemo- or chemoradiation therapy with transplant.

1. Substituting Taxol in Chemotherapy Regimen Preserves Ovarian Fun

A follow-up study of hundreds of pre-menopausal patients treated for early stage breast cancer at M. D. Anderson found that partial use of paclitaxel (TaxolTM) with standard adjuvant chemotherapy significantly improved a younger woman’s chance that she could regain her ovarian function.

The standard chemotherapy regimen, known as FAC, includes adriamycin and cyclophosphamide with or without 5-fluorouracil.

The analysis, culled from a larger study of 580 breast cancer patients, compared ovarian function and outcomes in younger women who received eight rounds of FAC versus patients who received four rounds of FAC followed by four rounds of paclitaxel.

In a group of 29 women who received just FAC treatment, 20 women (69 percent) had permanent loss of ovarian function, six women (21 percent) had a transient loss of ovarian function, and three patients (10 percent) never lost it. But in 59 women who had been treated with the "four plus four" regimen, 28 patients (47 percent) lost use of their ovaries, while 26 patients (44 percent) had a transient lost, and 5 patients (8 percent) never lost ovarian function.

Four women who used paclitaxel subsequently became pregnant, compared to just one patient treated only with FAC, reports Ibrahim.

The results are important because, at M. D. Anderson, up to half of all breast cancer patients treated are younger than 50 years old, says Ibrahim.

"This is not just an issue of fertility, but also of maintaining other healthy issues that are usually associated with premature menopause, such as osteoporosis, an increase of lipids in the blood stream and associated heart diseases, as well as sexual and cognitive health.

"If the clinical outcome between the patients treated with FAC alone or with FAC and paclitaxel is equivalent, then there is no reason not to offer the paclitaxel-based regimen for the patients who desire to preserve fertility, or to delay premature menopause," Ibrahim says.

2. Mini Transplants, Used to Treat Many Cancers, Can Save Ovaries

The second study found that in treating a variety of cancers with donor stem cell transplantation, use of low-dose chemotherapy was much better at preserving ovarian function than was high-dose chemotherapy.

The retrospective analysis included 3,945 patients who had received stem cell transplants between 1987 and 2001, and looked at the outcome of women younger than age 50 who were being treated for any malignancy other than breast or ovarian cancer.

Results show that of the 77 patients who received high-dose chemotherapy followed by stem cell transplantation, 79 percent lost ovarian function as seen in loss of their menstrual cycle. In contrast, 16 patients treated with low-dose chemotherapy and stem cell rescue (a so-called "mini-transplantation"), only 37.5 percent lost use of their ovaries.

"It’s very exciting to find a transplantation regimen that can protect a woman’s ovaries because this can truly be of benefit to our patients to improve long-term quality of life," says Ueno. "Of course, this can only be proven with a prospective trial, but it makes sense that a weaker regimen would be less toxic."

Mini transplants are most often used to treat leukemia, lymphoma and certain solid tumors.


Contact: Stephanie Dedeaux or Laura Sussman, (713) 792-0655


Laura Sussman | EurekAlert!

More articles from Health and Medicine:

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

nachricht Alzheimer’s: Cellular Mechanism Provides Explanation Model for Declining Memory Performance
21.09.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

Im Focus: Launch of New Industry Working Group for Process Control in Laser Material Processing

At AKL’16, the International Laser Technology Congress held in May this year, interest in the topic of process control was greater than expected. Appropriately, the event was also used to launch the Industry Working Group for Process Control in Laser Material Processing. The group provides a forum for representatives from industry and research to initiate pre-competitive projects and discuss issues such as standards, potential cost savings and feasibility.

In the age of industry 4.0, laser technology is firmly established within manufacturing. A wide variety of laser techniques – from USP ablation and additive...

Im Focus: New laser joining technologies at ‘K 2016’ trade fair

Every three years, the plastics industry gathers at K, the international trade fair for plastics and rubber in Düsseldorf. The Fraunhofer Institute for Laser Technology ILT will also be attending again and presenting many innovative technologies, such as for joining plastics and metals using ultrashort pulse lasers. From October 19 to 26, you can find the Fraunhofer ILT at the joint Fraunhofer booth SC01 in Hall 7.

K is the world’s largest trade fair for the plastics and rubber industry. As in previous years, the organizers are expecting 3,000 exhibitors and more than...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Experts from industry and academia discuss the future mobile telecommunications standard 5G

23.09.2016 | Event News

ICPE in Graz for the seventh time

20.09.2016 | Event News

Using mathematical models to understand our brain

16.09.2016 | Event News

 
Latest News

Chains of nanogold – forged with atomic precision

23.09.2016 | Life Sciences

New leukemia treatment offers hope

23.09.2016 | Health and Medicine

Self-assembled nanostructures hit their target

23.09.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>